CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 6103 participants.
Also called NCT01243424
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 6,103 participants
- Registry
-
NCT01243424 -
2009-013157-15
-
- Other papers using this trial's data
- Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Czechia, Finland, France, Georgia, Germany, Greece, Hong Kong SAR China, Hungary, India, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Norway, Peru, Philippines, Portugal, Romania, Russia, Serbia, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Tunisia, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01243424. Randomized; double masking; primary purpose treatment. Start 2010-11-11 (actual); primary completion 2018-08-21 (actual). Results posted on 2020-01-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- linagliptin
- Intervention (Drug)
- glimepiride
- Intervention (Drug)
- linagliptin placebo
- Intervention (Drug)
- glimepiride placebo
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01243424- Content hash
8fe484984049d26d3fdc4c08c311413375c22f6f46beec399689a2b53ba09cc7